Forskning ved Københavns Universitet - Københavns Universitet

Forside

3-O-methyldopa administration does not alter fluorodopa transport into the brain.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

3-O-methyldopa administration does not alter fluorodopa transport into the brain. / Guttman, M; Léger, G; Cedarbaum, J M; Reches, A; Woodward, W; Evans, A; Diksic, M; Gjedde, A.

I: Annals of Neurology, Bind 31, Nr. 6, 1992, s. 638-43.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Guttman, M, Léger, G, Cedarbaum, JM, Reches, A, Woodward, W, Evans, A, Diksic, M & Gjedde, A 1992, '3-O-methyldopa administration does not alter fluorodopa transport into the brain.', Annals of Neurology, bind 31, nr. 6, s. 638-43. https://doi.org/10.1002/ana.410310611

APA

Guttman, M., Léger, G., Cedarbaum, J. M., Reches, A., Woodward, W., Evans, A., Diksic, M., & Gjedde, A. (1992). 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology, 31(6), 638-43. https://doi.org/10.1002/ana.410310611

Vancouver

Guttman M, Léger G, Cedarbaum JM, Reches A, Woodward W, Evans A o.a. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology. 1992;31(6):638-43. https://doi.org/10.1002/ana.410310611

Author

Guttman, M ; Léger, G ; Cedarbaum, J M ; Reches, A ; Woodward, W ; Evans, A ; Diksic, M ; Gjedde, A. / 3-O-methyldopa administration does not alter fluorodopa transport into the brain. I: Annals of Neurology. 1992 ; Bind 31, Nr. 6. s. 638-43.

Bibtex

@article{20b87c20b31511debc73000ea68e967b,
title = "3-O-methyldopa administration does not alter fluorodopa transport into the brain.",
abstract = "To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 +/- 4 microM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.",
author = "M Guttman and G L{\'e}ger and Cedarbaum, {J M} and A Reches and W Woodward and A Evans and M Diksic and A Gjedde",
year = "1992",
doi = "10.1002/ana.410310611",
language = "English",
volume = "31",
pages = "638--43",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "JohnWiley & Sons, Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - 3-O-methyldopa administration does not alter fluorodopa transport into the brain.

AU - Guttman, M

AU - Léger, G

AU - Cedarbaum, J M

AU - Reches, A

AU - Woodward, W

AU - Evans, A

AU - Diksic, M

AU - Gjedde, A

PY - 1992

Y1 - 1992

N2 - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 +/- 4 microM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.

AB - To determine if 3-O-methyldopa (3OMD) significantly inhibits the transport of 6-[18F]fluorodopa (6-FD) into the brain at the concentration normally encountered during L-dopa administration, we performed 6-FD studies with positron emission tomography in cynomolgus monkeys in the presence and absence of 3OMD. Infusion of 3OMD was designed to produce plasma concentrations equivalent to those seen in patients on chronic L-dopa therapy. Plasma 3OMD levels of 39 +/- 4 microM did not alter the blood-brain transfer rate of 6-FD. 6-FD positron emission tomographic studies in parkinsonian patients will therefore not be altered by 3OMD present in the blood in those patients taking L-dopa preparations. These results do not support the hypothesis that transport of L-dopa into the brain is inhibited by 3OMD to cause the declining response seen in patients with advanced Parkinson's disease.

U2 - 10.1002/ana.410310611

DO - 10.1002/ana.410310611

M3 - Journal article

C2 - 1514775

VL - 31

SP - 638

EP - 643

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -

ID: 14944932